Markets:

Overview

News

Currencies

International

Treasuries

ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

21.61 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Feb 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about ACADIA Pharmaceuticals Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

March 12, 2024

Pre-market stock movers are worth checking out this morning as we get into all of the biggest winners and losers for Tuesday!

Via InvestorPlace

Trial Setback For Acadia Pharmaceuticals' Late-Stage Schizophrenia Trial: Details ↗

March 12, 2024

Acadia Pharmaceuticals' Phase 3 ADVANCE-2 trial results on pimavanserin for schizophrenia-negative symptoms. Insights on efficacy, safety, and future considerations.

Via Benzinga

ACADIA Pharmaceuticals, Ocular Therapeutix, Asana And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

March 12, 2024

U.S. stock futures were mixed this morning, with the Nasdaq futures gaining by around 50 points on Tuesday.

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

March 11, 2024

Via Benzinga

Beyond The Numbers: 13 Analysts Discuss ACADIA Pharmaceuticals Stock ↗

February 28, 2024

Via Benzinga

Recap: ACADIA Pharmaceuticals Q4 Earnings ↗

February 27, 2024

Via Benzinga

Earnings Scheduled For February 27, 2024 ↗

February 27, 2024

Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million.

Via Benzinga

3 Stock Winners That Are Up 1,000% or More in 2024 ↗

March 08, 2024

Dig deep enough, and find a story hot enough, and you can uncover potential stock winners up 1,000%. Here are three.

Via InvestorPlace

Acadia Stock Dives As Unexpected Seasonality Rocks Its Most High-Profile Launch ↗

February 28, 2024

CEO Steve Davis said there was a lot of pent-up demand when Daybue first launched last year.

Via Investor's Business Daily

The 3 Most Undervalued Biotech Stocks to Buy in February 2024 ↗

February 08, 2024

With patience, some of the most undervalued biotech stocks can create massive wealth, such as these three to consider.

Via InvestorPlace

Analyst Scoreboard: 12 Ratings For ACADIA Pharmaceuticals ↗

January 24, 2024

Via Benzinga

Expedia To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Friday ↗

December 29, 2023

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Deep Dive Into ACADIA Pharmaceuticals Stock: Analyst Perspectives (13 Ratings) ↗

December 29, 2023

Via Benzinga

Analyst Ratings for ACADIA Pharmaceuticals ↗

December 12, 2023

Via Benzinga

What 7 Analyst Ratings Have To Say About ACADIA Pharmaceuticals ↗

November 06, 2023

Via Benzinga

Acadia Soars To A Four-Month High After Winning A Patent Battle For Its Biggest Drug ↗

December 13, 2023

MSN Labs lost out in a summary judgement to knock off Acadia's Nuplazid.

Via Investor's Business Daily

Topics Intellectual Property

What's Going On With Acadia Pharmaceuticals Stock? ↗

December 13, 2023

Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) shares are trading higher Wednesday after the company won summary judgement in a patent suit regarding its Nuplazid drug. What To Know:

Via Benzinga

Topics Intellectual Property

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

December 13, 2023

Via Benzinga

3 Biotech Stocks With the Strongest Clinical Pipelines ↗

November 08, 2023

Many industry heavyweights are on the hunt for fresh new ideas -- great news for biotech stocks to buy with strong pipelines.

Via InvestorPlace

10 Health Care Stocks Whale Activity In Today's Session ↗

November 02, 2023

Via Benzinga

Analyst Ratings for ACADIA Pharmaceuticals ↗

October 10, 2023

Via Benzinga

Why Acadia Pharmaceuticals Stock Is Rising Today ↗

October 10, 2023

An analyst upgrade is sparking a rally in the drugmaker's shares today.

Via The Motley Fool

2 Growth Stocks I'd Buy on the Dip ↗

September 30, 2023

These two growth stocks could be worthwhile buy-and-holds.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023 ↗

October 17, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 10, 2023 ↗

October 10, 2023

Via Benzinga

Electronic Arts To Rally Over 20%? Here Are 10 Other Analyst Forecasts For Tuesday ↗

October 10, 2023

JP Morgan increased ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) price target from $29 to $32. JP Morgan analyst Tessa Romero upgraded the stock from Neutral to Overweight. ACADIA Pharmaceuticals shares...

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

October 02, 2023

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

September 28, 2023

Via Benzinga

Why CarMax Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

September 28, 2023

Gainers Bionomics Limited (NASDAQ: BNOX) shares jumped 308% to $4.00 after the company announced the ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant...

Via Benzinga

2 Supercharged Growth Stocks Billionaires Can't Stop Buying ↗

August 28, 2023

A top hedge fund has been steadily buying these two growth stocks in 2023.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

Headline News about ACADIA Pharmaceuticals Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today